Mariner’s VYNE Therapeutics VYNE Stock Holding History

Mariner’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-694	Closed	-$2K	–	2886
2022 Q4	$2K	Sell	694 -82	-11%	-$328	﹤0.01%	2734
2022 Q3	$3K	Buy	+776	New	+$4.97K	﹤0.01%	2436

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Mariner's VYNE Position: Q1 2023 in Review

Mariner sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 694 shares — an estimated $2K sold.

Mariner first reported a position in VYNE in Q3 2022 and held it in 2 quarters. The position peaked at $3K in Q3 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

Mariner reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
Mariner sold 694 VYNE Therapeutics shares in Q1 2023, an estimated $2K.
Mariner first reported a position in VYNE Therapeutics in Q3 2022 and held it in 2 quarters.
Mariner's VYNE Therapeutics position peaked at $3K in Q3 2022.
23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.